Dasatinib induces a response in chronic lymphocytic leukemia.
Pitini
Vincenzo
V
Arrigo
Carmela
C
Altavilla
Giuseppe
G
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001549:Benzamides; D001772:Blood Cell Count; D000069439:Dasatinib; D005260:Female; D016044:Fusion Proteins, bcr-abl; D006470:Hemorrhage / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007579:Jejunal Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011743:Pyrimidines / Q000008:administration & dosage*; D012074:Remission Induction; D000069283:Rituximab; D013844:Thiazoles / Q000008:administration & dosage*; D014057:Tomography, X-Ray Computed; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D019061:src-Family Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069283:Rituximab; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D019061:src-Family Kinases; D014740:Vidarabine; C024352:fludarabine; D000069439:Dasatinib